Start here if you're new
what it is
JBT Marel sells the machines, software, and service contracts that keep large food plants moving.
how it gets paid
Last year Jbt Marel made $3.8B in revenue. Equipment systems was the main engine at $1.90B, or 50% of sales.
why it's growing
Revenue grew 121.3% last year. Revenues grew 7% sequentially and were $65 million above our forecast.
what just happened
JBT Marel beat on adjusted EPS, but the cleaner read is that Revenue hit $2.8B after the merger reset the scale.
At a glance
B++ balance sheet — above average — nothing keeping you up at night
85/100 earnings predictability — you can trust these numbers
24.5x trailing p/e — priced about right
0.3% dividend yield — cash in your pocket every quarter
10.0% return on capital — nothing to write home about
xvary composite: 62/100 — average
What they do
JBT Marel sells the machines, software, and service contracts that keep large food plants moving.
This business wins because food processors hate downtime more than they hate writing checks. Half of 2024 revenue was recurring, which means 50% of sales came from repeat parts, service, and other repeat work instead of one-off equipment orders. Switching costs (changing suppliers) → replacing installed machines, retraining staff, and risking production delays → so what: once your plant runs on this gear, leaving gets expensive fast.
How they make money
$3.8B
annual revenue · their business grew +121.3% last year
Equipment systems
$1.90B
Aftermarket service
$1.14B
Software and automation
$0.76B
The products that matter
processes meat and poultry
Protein Solutions
$1.9B · roughly half of revenue shown here
This is a $1.9B business tied to protein processing lines. It gives you scale in a mission-critical part of food production, but it still moves with plant-spending cycles.
equipment + service
handles beverages and prepared foods
Prepared Food & Beverage
$1.9B · the other major operating bucket
Another $1.9B sits here across liquid food, beverage, and packaged-food lines. The diversification helps. It does not remove execution risk from a fresh merger.
scale matters
parts, software, and maintenance
Recurring Services & Parts
50% of revenue mix · about $1.9B
This is the revenue stream carrying the premium story. If half of sales repeat, the business deserves more credit than a one-and-done equipment seller. If that mix slips, the stock loses its main defense.
repeat revenue
Key numbers
$3.8B
annual revenue
Revenue jumped 121.3% vs. prior year, which tells you the Marel combination changed the size of this business overnight.
5.0%
operating margin
Operating margin (profit after running the business) → what the core business keeps before interest and taxes → so what: this is still a low-margin operation.
24.5x
trailing p/e
Trailing P/E (price divided by past earnings) → how much you pay for what it already earned → so what: you are paying a full price for a company still integrating a major deal.
$1.5B
long-term debt
Debt is manageable at 16% of capital, but it still limits your margin for error if integration savings arrive late.
Financial health
B++
strength
- balance sheet grade B++ — above average financial health
- risk rank 3 — safer than 50% of stocks
- price stability 50 / 100
- long-term debt $1.5B (16% of capital)
- net profit margin 10.8% — keeps 11 cents of every dollar in revenue
- return on equity 14% — $0.14 profit for every $1 investors have put in
B++ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in JBTM 3 years ago → it's now worth $17,780.
The index would have given you $13,920.
source: institutional data · total return
What just happened
beat estimates
JBT Marel beat on adjusted EPS, but the cleaner read is that Revenue hit $2.8B after the merger reset the scale.
Last earnings came in at $1.98 versus a $1.95 estimate, a 1.54% beat by Yahoo Finance data. Management says revenue grew 7% sequentially and landed $65 million above its forecast, helped by early cross-selling and faster-than-expected integration gains.
$950M
revenue
$1.98
eps
n/a
n/a
the number that mattered
The number that mattered was $65 million above forecast revenue, because it suggests the merger is producing real sales lift, not just presentation slides.
-
benefits from the merger integration at jbt marel are being achieved faster than expected.
-
john bean technologies and marel hf combined in early january of 2025.in its second full quarter after the transaction, both the top line and the bottom line exceeded our estimates in the september quarter.
-
revenues grew 7% sequentially and were $65 million above our forecast.
-
the company has been able to cross sell into each others customer bases.
-
most of jbt's business came from north america and marel's focus was mostly on the european market.each firms' food processing and packaging equipment also served different functions on the production line.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
this is not a vague "industrials are risky" story. The risk is specific: a $6.7B deal, a $600M EBITDA promise, and a business where only about half of revenue repeats on its own.
med
merger integration slips
The whole case rests on combining JBT and Marel without losing sales momentum, margin discipline, or customer focus. If that process drags, the market stops paying for future improvement and starts pricing present friction.
The direct hit lands on the $600M adjusted EBITDA target — the number carrying a lot of the valuation story.
med
equipment demand cools
About half of revenue is not recurring. That means roughly $1.9B still depends on food and beverage customers approving large capital projects, and those budgets can get delayed quickly.
A capex slowdown pressures the non-recurring half first, which is exactly where you do not want softness during an integration cycle.
med
cross-selling proves slower than expected
One reason this deal made sense was geography and product fit — JBT stronger in North America, Marel stronger in Europe, with different roles on the production line. If those sales motions do not travel well, the revenue case stays stuck on paper.
That would leave 24.5x trailing earnings looking expensive for a business with 10.8% net margins and a 0.3% yield.
med
margin gains stall while debt stays real
A B++ balance sheet and $1.5B of long-term debt are manageable numbers. They are not an excuse for sloppy integration. If margin improvement stalls, leverage feels heavier fast even without a balance-sheet crisis.
That weakens the whole rerating case, because you are left with average margins, merger complexity, and less patience from the market.
A miss here is not abstract. It hits the recurring-revenue premium, the 5–7% growth outlook, and the $600M EBITDA destination at the same time.
source: institutional data · regulatory filings · risk analysis
Pay attention to
ebitda target
progress toward $600M
This is the merger scoreboard. If management stops showing a credible path to $600M of adjusted EBITDA, the stock loses its integration premium.
earnings
Q1 2026 earnings report
Expected May 4, 2026. You want to see whether the 5–7% growth guide still holds after another quarter of integration work.
mix shift
recurring revenue holding near 50%
That 50% recurring mix is the number that makes this feel steadier than a normal equipment business. If it slips, the valuation case gets thinner fast.
demand risk
customer capex appetite
Half the revenue base still depends on large machine orders. Watch order commentary for any slowdown in protein, beverage, or prepared-food spending.
Analyst rankings
earnings predictability
85 / 100
High score, simple translation: management usually lands close to guidance. in human-speak, analysts think the business is easier to model than the average industrial name.
risk rank
3
Risk rank 3 means safer than about 50% of stocks. That is decent, not defensive.
source: institutional data
Institutional activity
institutions have been net buying for 3 consecutive quarters — 193 buyers vs. 147 sellers in 3q2025. total institutional holdings: 48.8M shares. net buying for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$113
$258
$156
current price
$186
target midpoint · +20% from current · 3-5yr high: $225 (+45% · 10% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive